GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing
Outside of vaccines, GlaxoSmithKline isn’t a major producer of biologics compared with some of its Big Pharma peers. But it has just signed a big deal to scale up manufacturing in the field. The British pharma tapped South Korean CDMO Samsung Biologics in a deal worth more than $ 231 million to help it make biologic… Read More »